81 Flinders Street
Level 8
Adelaide, SA 5000
Australia
61 4 3802 7172
https://anataralifesciences.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS | Executive Chairman | 168,21k | N/A | 1960 |
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. | COO & Executive Director | 118,79k | N/A | N/A |
Mr. Simon Erskine | Chief Development Officer | 235,21k | N/A | N/A |
Jane Lowe | Managing Director of IR Department | N/A | N/A | N/A |
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD | Company Secretary | N/A | N/A | N/A |
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management | Commercial Manager | N/A | N/A | N/A |
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Anatara Lifesciences Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.